Connection
Joseph Saseen to Antibodies, Monoclonal
This is a "connection" page, showing publications Joseph Saseen has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.300 |
|
|
|
-
Dixon DL, Saseen JJ. Pharmacist-administered long-acting injectable PCSK9 service: A solution to improve patient access and adherence. J Am Pharm Assoc (2003). 2021 May-Jun; 61(3):e83-e85.
Score: 0.110
-
Robinson JG, Jayanna MB, Brown AS, Aspry K, Orringer C, Gill EA, Goldberg A, Jones LK, Maki K, Dixon DL, Saseen JJ, Soffer D. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. J Clin Lipidol. 2019 Jul - Aug; 13(4):525-537.
Score: 0.098
-
Nair KV, Tang B, Van Den Bos J, Zhang V, Saseen JJ, Naim A, Rahman M. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Curr Med Res Opin. 2009 Feb; 25(2):303-14.
Score: 0.048
-
Saseen JJ. Putting new disease-modifying antirheumatic drugs into perspective. Pharmacotherapy. 2007 Dec; 27(12):1609-10.
Score: 0.044